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Abstract
Soy, which contains a form of phytoestrogen known as isoflavones, impacts the biological activity of humans at all stages. There 
are many aspects to consider when determining whether soy is beneficial. Since the hormone estrogen plays a significant role 
in maintaining the biochemical and homeostatic conditions of an individual, it follows that the disruption of estrogenic levels can 
be detrimental. There are many hormone- dependent diseases that can be linked to one’s diet, and the possibility of utilizing 
phytoestrogens, such as soy, to prevent or control hormonal irregularities is compelling . This paper explores the effects that phy-
toestrogens, specifically soy, can have at various stages of hormonal progression.
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Introduction
Recently, soy has been garnering attention for its estro-
gen-like qualities. One group of chemicals found in soy are 
phytoestrogens, a non-steroidal class of estrogens. Of the 
numerous phytoestrogens, the study of the role of isofla-
vones has been isolated because of their high concentra-
tion in soy. Crucial to understanding soy’s “estrogen-like” 
qualities is understanding isoflavones’ chemical makeup. 
In soy specifically, isoflavones present as glycosides, which 
are bound to sugar molecules. When the isoflavone gly-
cosides are digested and released, the isoflavone presents 
as aglycones. This includes compounds such as genistein, 
daidzein, and glycitein. 
Structurally, these isoflavones are similar to a form of 
estrogen, 17β-estradiol, as shown (fig, 1). The phenolic 
ring on the isoflavones is a crucial part of its structure 
which chemically allows the phytoestrogen to attach to 
estrogen receptors, thus promoting “estrogen-like” activ-
ity. Once the isoflavone is bound to an estrogen-recep-
tor complex, the phytoestrogen can act as an estrogen 
agonist or antagonist. Based on various factors, such as 
the concentration levels of the phytoestrogen and endog-
enous estrogen, the specificity of the receptor, and the 
particular tissue that the phytoestrogen is targeting, the 
soy will either act as an estrogen inhibitor or stimulant. 
This holds promise as a physiologically beneficial meth-
od of regulating hormonal abnormalities. Dietary estro-
gen has shown potential in alleviating postmenopausal 
symptoms, reducing the risk of breast cancer, and bone 
resorption. However, soy is dosage- dependent, and a 
high intake of soy in infancy may lead to some physical 
signs of sexual maturation at a young age. Soy has also 
been a contributing factor for both very early and late 
menarche. There is a concern for early maturation, as it 
can cause hormone- related cancers such as breast can-
cer. Therefore, the consumption of soy that leads to the 
binding of isoflavones to sex-hormone binding globulins 
(SHBG) necessitates much research to determine all pos-
sible outcomes (Setchell, 1998).
Methods
The following research is based on the analysis of numer-
ous articles from various databases, that include but are 
not limited to The Touro College Library online, PubMed, 
and ProQuest. The National Center for Biotechnology 
(NCBI), and BioMed Central (BMC) were additional 
sources of data as well.
Discussion 
Infants
Soy- based infant formula (SBIF) has been used for over 
100 years. SBIFs were developed as an alternative to 
cow’s milk-based formula for infants that were lactose in-
tolerant or required vegan replacement. Recent data has 
shown that SBIF is used by approximately 20%-25% of 
Americans. SBIF has a high concentration of isoflavones; 
the concentration levels vary from 32 to 47 mg isofla-
vones/L of formula. According to research, “infants fed 
SBIF are exposed to a 6–11 fold higher level of isoflavones 
on a body weight basis than adults. Additionally, circulat-
ing isoflavone levels of these infants were 13,000–22,000 
times greater than circulating levels of 17-β-estradiol.” 
(Dinsdale et al., 2010) The effect of an infant consuming 
and absorbing this high of a dosage of an estrogenic- 
like substance can have long-term consequences. This is 
because SBIF is primarily used from birth to one years 
old, which is a stage of development that is “particular-
ly sensitive to dietary and environmental compounds.” 
However, it is exceedingly difficult to track soy formu-
la’s precise long-term effects on reproductive health. In 
order to so, all participants must be monitored before 
reaching puberty and all through the child-bearing years; 
this would allow the possible differences in reproductive 
health and organ development to be determined. Since 
that would require long-term compliance, a retrospec-
tive approach has been taken to analyze the effects on 
those who consumed SBIF. However, as a retrospective 
study, there are the limitations of recall bias and environ-
mental differences, such as smoking, physical activity and 
history of diseases, which make it difficult to determine 




the accuracy of the results. No reports were given of 
long-term adverse effects for the male infants fed SBIF.  At 
six months of age, female infants were reported to have 
increased vaginal cell maturation. There did not seem to 
be any vaginal discharge or breast development that was 
out of the ordinary. However, when children at two- years 
-old were still fed SBIF, there was an increase in the per-
vasiveness of breast tissue development in these children. 
Furthermore, the study reported that formula feeding 
in general, whether soy- or cow’s milk-based, can cause 
greater ovarian volume, an increase in the numbers of 
ovarian cysts per ovary, and lower testicular volume. 
On the other hand, SBIF and soy in general seem to pre-
vent breast cancer. High levels of isoflavone enhance differ-
entiation of the mammary glands, which leads to greater 
protection against chemically-induced mammary cancer. 
This was proven through a study in which genistein treat-
ment was given, resulting in “fewer terminal end buds and 
advanced development and ductal elongation.” As the least 
mature terminal ductal structures, it follows that terminal 
end buds are the most susceptible to possible carcinogens. 
Therefore, reducing the number of terminal end buds can 
lead to lower incidences of breast cancer. This is due to 
the fact that, “Part of the terminal end bud differentiates 
according to each estrous cycle, giving rise to alveolar buds 
that consist of lobule structures that are more mature and 
less susceptible to chemical carcinogens.” This treatment 
of genistein increased the number of lobules, which shows 
that there is a potential protective effect against mamma-
ry cancer. The exact mechanism in which genistein affects 
mammary gland development is unclear; however, accord-
ing to these findings, genistein clearly displayed estrogenic- 
like behavior (Dinsdale et al., 2010). 
Further studies show that high soy exposure during the 
prenatal and infant stages can cause early onset puberty, 
specifically menarche. Early menarche (≤10-11 years old) 
is just one of the factors that are considered when de-
termining whether a female reached puberty; however, it 
is the most commonly used benchmark. There are many 
issues associated with early development, such as adult 
obesity, type 2 diabetes, metabolic syndrome, and other 
markers of cardiovascular disease. A study was done to 
determine the various factors involved in early menarche, 
soy being among them. The Sister Study enrolled 50,884 
American and Puerto Rican women between the ages of 
35-74. The study was interested in finding whether certain 
early-life exposures are related to the health conditions 
mentioned above. The authors conducted interviews that 
included a comprehensive family medical history. Anyone 
that did not have a mother to relate the early life events 
was excluded. The study combined those that said they 
“definitely” or “probably” had feeding exposures into one 
category, and those that responded that they “definitely 
did not” and “probably did not,” into another category. 
Race/ethnicity, maternal age menarche, birth weight, birth 
decade, and childhood family income were also factored 
into the results. Results showed that, “The frequency of 
early menarche (≤11 years) was 20%, with 7% reporting 
menarche at 10 years of age or younger. The frequency of 
late menarche (≥14 years) was 24%, with 10% reporting 
menarche at 15 years of age or older.” 
The table above shows that SBIF can cause both early 
(≤10 years old) and very late menarche (≥15 years old). 
Although age at menarche is not the only sign of puber-
tal development, it is a key component; therefore, these 
studies are an important resource to tracking pubertal 
development. These findings are 
consistent with animal data that 
proves that the dose of genistein 
impacts whether early or late 
puberty will occur. “Mice admin-
istered a higher dose of genistein 
had a delayed vaginal opening 
(marker of puberty), while mice 
given a lower dose had an accel-
erated vaginal opening. Neonatal 
administration of genistein to 
mice has also produced other 
alterations in reproductive char-
acteristics, including changes in 
estrous cycles, early reproductive 
senescence, and decreased fertil-
ity.” In other words, the effects 
of neonatal administration of 
Table 1
Relative Risk Ratios for Early and Late Menarche in Association with Early-Life Exposures in 
Women Aged 35 to 59 years at Baseline in the Sister Study, 2003-2009 (n = 33,501)  
(D’Aloisio et al., 2013)
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genistein were greater than when genistein was admin-
istered to older mice. This makes sense considering that 
soy formula delivers a high dosage of its estrogenic com-
ponents to infants “per unit body weight.” Additionally, 
genistein is highly digestible and has been found in high 
concentrations in infants’ urine and plasma. Thus, main-
taining that the genistein can influence the estrogenic- 
like effect on these infants (D’Aloisio et al., 2013). 
Furthermore, while there is no evidence that SBIF 
directly effects reproduction, SBIF does exert its influ-
ence on the menstrual cycle. Women who were given 
soy formula as infants reported prolonged menstruation 
and more discomfort. With all this data, the question of 
whether or not soy formula is safe remains. Many coun-
tries have regulations on the use of SBIF. For instance, in 
Europe, SBIF is a prescribed product. However, despite 
these regulations, there is a large percentage of infants 
each year that are fed SBIF (Dinsdale et al., 2010).
Male Reproduction
Considering isoflavones’ estrogenic qualities, it follows 
that there can be estrogenic effects on males that con-
sume high concentrations of soy. There are not many 
cases reported of soy stimulating feminizing effects on 
men, such as gynecomastia. However, a study was done 
on an instance of hypogonadism and erectile dysfunction 
that was linked to high intake of soy.  A 19-year-old male 
that was recently diagnosed with type 1 diabetes began 
experiencing complete loss of libido and erectile dys-
function. Until the previous year, he had been in perfect 
health. He stated he had a heterosexual preference, was 
sexually active, had satisfactory libido, denied any history 
of orchitis or undescended testicles, had normal testic-
ular size, and body hair pattern. Additionally, he denied 
any androgen abuse, hormonal medication, drug abuse, or 
psychiatric disorders. He had never had a sexually trans-
mitted disease, no visual or muscular mass and strength 
changes, and no headaches. The one notable difference in 
his lifestyle was that he had taken on a vegan diet, which 
included high levels of soy (360 mg/day), due to his recent 
diagnosis of diabetes. A lab assessment revealed that he 
had low free and total testosterone levels, with increased 
levels of dehydroepiandrosterone (DHEA). His symptoms 
began after he started his vegan diet, which included 
products such as soy milk, soy cookies, tofu, soy sauce, 
soy nuts, and soybeans. Beforehand, he had been consum-
ing the average American 2,000- kcal diet. After stopping 
his vegan and soy diet, his symptoms improved over the 
course of 12 months. These improvements were consis-
tent with the gradual normalization of his testosterone 
and DHEA levels. The table below shows the progression 
of the patient’s levels of total and free testosterone, as 
well as the levels of DHEA normalizing over a period. 
The insufficient blood levels of free testosterone, which 
causes hypogonadism and erectile dysfunction, normal-
ized after the cessation of the soy diet, indicating that the 
high levels isoflavones may have been the cause.
The correlation between testosterone and soy may be 
explained by research on animals. “Animal studies have 
shown that isoflavones can bind to the estrogen receptor 
expressed by testosterone-producing Leydig cells, there-
by affecting Leydig cell differentiation and testosterone 
production, which ultimately leads to reproductive tox-
icity.” Therefore, consuming high levels of isoflavones can 
stimulate similar bioactivity in males.  Another possibility 
is that the estrogen- like isoflavones can cause a nega-
tive feedback mechanism that interferes with the DHEA 
conversion to testosterone. As the DHEA converting 
enzymes 3-b-hydroxysteroid dehydrogenase and 17-b-hy-
droxysteroid dehydrogenase are inhibited through the 
isoflavones genistein and daidzein present in soybean, the 
negative feedback is facilitated. The inhibition is what can 
lead to a decrease in testosterone. Another possible way 
in which the isoflavones decreased the free testosterone 
levels can be through the increase of the sex hormone- 
binding globulin (SHBG), which is produced by the estro-
genic activities of isoflavones. The increase of SHBG leads 
to more binding of the SHBG with the total circulating 
testosterone, which means there will be less free testos-
terone; this also further explains why the total circulat-
ing testosterone levels were within 
normal range (table 2). However, 
because there were missing SHBG 
measurements during the vegan diet, 
this hypothesis cannot be confirmed. 
There were nine more studies done 
in which the highest level of isofla-
vone concentration given was 139 
mg/d, as opposed to the 360 mg/d 
given in this study. As this was the 
only study done that there was 
clearly a testosterone decrease with 
Table 2
(Partial) Hormone profile at cessation of vegan diet and during 2-y follow-up (Siepmann et al., 2011)
20
Anne Roberts
the consumption of soy, researchers speculate that there 
is an “isoflavone intake threshold” for symptoms to occur. 
There is also the possibility that since the composition 
of soy products has evolved over the years, there might 
have been differences in the soy products of the previ-
ous studies. While further studies are necessary, this case 
report successfully indicates that a high consumption of 
isoflavones is related to hypogonadism and decreased 
free testosterone (Siepmann et al., 2011).
Menopause
Phyto-estrogens that are administered in an environment 
that has a high concentration of endogenous estradiol 
have an antagonist effect on the estrogen receptors. In 
that case, the isoflavones act as an inhibitor. However, 
when there is a decrease of endogenous estrogen, such 
as hypogonadism and menopause, an administration of 
isoflavones will stimulate estrogenic bioactivity (Casini et 
al., 2006). Menopause symbolizes the end of a women’s 
reproductive life and is characterized by the cessation 
of menstrual periods for 12 consecutive months, which 
normally occurs between 45-55 years of age. Aside from 
the cessation of menstrual periods, there are additional 
symptoms, such as hormonal disturbances, hot flashes, 
night sweats, sleeping disorders, vaginal dryness, joint pain, 
mood swings, reduced bone density, and cardiovascular 
disease (Sunita et al., 2011). This mainly occurs because 
the menopause transition results in estrogen deficiency. 
Estrogen regulates appetite, cholesterol levels, carbohy-
drate and lipid metabolism, and protects bone. Therefore, 
when a woman is estrogen- deficient, the possibility of 
obesity, osteoporosis, and cardiovascular disease is more 
prevalent. To combat the hormonal imbalance, there are 
various forms of hormone replacement therapies (HRT). 
However, there are a host of issues with the with the 
HRT available, because the treatments available can cause 
diseases such as thromboembolism, uterine hyperplasia, 
uterine cancer, increased risk of breast, ovarian, and en-
dometrial cancers, coronary heart disease, and stroke. 
Therefore, in more recent years women have been turn-
ing toward more natural methods of HRT, such as soy, 
to alleviate menopausal symptoms. Genistein promotes 
an inhibitory effect on many of the common menopaus-
al symptoms. “It should be noted that genistein acts on 
various molecular pathways to emulate the effects of es-
trogens, without being known to elicit any life-threatening 
adverse effects.” There have been studies done to deter-
mine how effective this form of therapy may be; howev-
er, this is still a relatively recent discovery and there are 
many aspects that need further exploration (Thangavel 
et al., 2019).
The Asian diet is heavenly concentrated with soy, rela-
tive to the European and American diet. Statistically, only 
20%-25% of Asian postmenopausal women experience 
hot flashes, whereas 70%-80% of European and Latin 
American postmenopausal women complain of hot flash-
es. Since these hot flashes are one of the main postmeno-
pausal symptoms that women seek HRT for, researchers 
were compelled to discover what caused Asian women 
to have a lower incidence rate (Thangavel et al., 2019). 
There are a few studies that have reported the effective-
ness of genistein in treating hot flashes. A study was done 
on Japanese women specifically, comparing soy intake to 
incidences of hot flashes. This study was conducted over 
six years, in which it was shown that the consumption 
of soy reduced the hot flashes considerably. Even at the 
lowest concentration of isoflavones (75.2- 115.9 g/day), 
the hot flashes were lower, but the response rate was 
definitely more successful in the women that consumed 
higher levels of soy (Nagata et al., 2001). Another study 
was done on menopausal women and found that the “ad-
ministration of 30 mg of genistein for 12 weeks reduced 
hot flashes by 51% (9.4–4.7/day), whereas the placebo 
group experienced only a 27% reduction (9.9–7.1/day).” 
(Braxas et al., 2019) Furthermore, a randomized trial was 
conducted in which hot flashes were alleviated by the 
consumption of 54 mg/day over the course of a year. The 
mechanism in which genistein can inhibit the hot flashes is 
unclear. However, researchers speculate that the genistein 
diffuses through the cell’s lipid bilayer “due to genistein 
being an effective ER (estrogen receptor) modulator.” 
This will set off the mRNA synthesis and production 
of tissue-specific proteins (Crisafulli et al., 2004). While 
there is no definite conclusion as to why genistein inhibits 
hot flashes, it seems to be a successful method based on 
the results of the numerous studies above. 
Another effect that occurs because of estrogen deple-
tion is the change in metabolism, such as the slowing down 
of the body’s ability to metabolize carbohydrates and lipids. 
Consequently, women in the menopause stage are suscep-
tible to weight gain. Genistein was found to stimulate a 
metabolic rate of carbohydrates and lipids to help prevent 
weight gain. This occurs because genistein regulates ad-
ipose tissue by restricting lipogenesis and enhancing lip-
olysis in adipocytes (Szkudelska et al., 2007). Furthermore, 
phytoestrogen treatment “reduced obesity markers, such 
as total cholesterol and low-density lipoprotein (LDL) cho-
lesterol.” These are common markers that are associated 
with obesity and cardiovascular health (Jayagopal et al., 
2002).  Additionally, another study reported that after 6 to 
12 months of 54 mg/day of genistein treatment there was a 
significant reduction in triglycerides, total cholesterol, and 
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LDL-cholesterol (Squadrito et al., 2013). Conclusively, soy 
treatment can potentially improve cardiovascular health 
and prevent obesity.  
There seems to be a positive correlation between a 
soy rich diet and the inhibition of cancers, specifically 
breast cancer. SBIF can inhibit breast cancer as well. Most 
of the studies compared the association of soy-rich diet 
with reduced breast cancer in Asian women, compared to 
those in the Western world. In one case, an Asian woman 
who migrated to a Western country showed an increased 
risk for cancer. The risk of breast cancer increases with 
age, and this form of cancer has become one of the most 
common forms of cancer affecting women. As the com-
mon forms of HRT are known to increase the risk of 
developing breast cancer, natural methods are a compel-
ling substitute. Genistein, the form of isoflavone that is 
the most abundant in soy, has shown anticancer prop-
erties in preclinical trials, thereby opening the option of 
attempting clinical trials. Since this bioactive compound, 
soy, induces apoptosis in various cancer cell lines, such as 
HepG2 and Hep3B, in- vitro studies have proven the effi-
cacy of genistein as a promising chemotherapeutic agent 
against cancer. Table 3 summarizes some of the common 
menopausal symptoms and how genistein can alleviate 
the symptoms (Thangavel et al., 2019). 
In addition to the diseases mentioned above, osteo-
porosis is another disease that postmenopausal women 
are prone to. Since estrogen has bone- protecting prop-
erties, it follows that a lack of estrogen puts menopausal 
women at risk of developing osteoporosis. Soy has been 
reported to reduce the risk of osteoporosis in peri- and 
post-menopausal women. A study was done examining 
the effects of a heavy soy diet on the overall bone densi-
ty and strength of postmenopausal women. Eighty-seven 
women were eligible and were assigned to consume soy 
or control foods daily for one year. “Bone mineral density 
(BMD) and bone mineral content (BMC) of the whole 
body, lumbar (L1-L4), and total hip were measured using 
dual energy x-ray absorptiometry at baseline and after 
one year (Arjmandi et al., 2005).” Additionally, urine and 
blood markers of bone metabolism were assessed. Of 
the eighty-seven women, sixty-two completed the one-
year long study. Results showed that whole body and 
lumbar BMD and BMC decreased in both the soy and 
control groups. However, the total hip BMD and BMC 
did not change in either group. “Both treatments posi-
tively affected markers of bone formation as indicated 
by increased serum bone specific alkaline phosphatase 
(BSAP) activity, insulin-like growth factor-I (IGF-I), and 
osteocalcin (BSAP: 27.8 and 25.8%, IGF-I: 12.8 and 26.3%, 
osteocalcin: 95.2 and 103.4% for control and soy groups, 
respectively).” (Arjmandi et al., 2005) Neither group had 
any effect on urinary deoxypyridinoline excretion, which 
is a marker of bone resorption. However, according to 
epidemiological data, populations with soy rich diets, such 
as the Asians, do have a lower incidence of 
osteoporotic fractures. On the other hand, 
there are numerous factors that contribute 
to skeletal health; therefore, the credit of the 
lower rates of fractures in these populations 
cannot be fully attributed to soy consumption. 
There are a number of animal studies that did 
show how isoflavones positively influenced 
BMD. However, when it comes to human 
studies there are a limited number of studies 
that examined the effects of soy on bone. A 
study was set up in which the identity of the 
individual treatments was only revealed after 
the analysis was complete, to keep the results 
as accurate as possible. Compliance of the 
participants was measured based on whether 
participants recorded the amount of soy they 
consumed and if they returned the uneaten 
food to the study site to be tallied. This study 
did not show that soy protein alone can sub-
stantially prevent bone loss. However, another 
study did indicate that a consumption of 40 mg/day to 80 
mg/day for a year resulted in positive increases in BMC 
of the hip of the women who are at least four years post 
menopause. Additionally, these women were of low body 




done in which there was no substantial effect of soy on 
reversing bone loss, most of the participants were four 
years post-menopause; however, many did not have low 
body weight or calcium intake. Therefore, it is possible 
that the differences in these factors are what created the 
discrepancy of the observed results of the bone (Chen 
et al., 2004). As far as which form of isoflavones is the 
most beneficial when it comes to affecting the bone, ac-
cording to studies genistein is the single isoflavone with 
the greatest effect. A study demonstrated that genistein 
at a dose of 54 mg/d combined with HRT increased BMD 
in early postmenopausal women. Genistein was proven 
to increase the BMD of the femoral neck by 3.6% and 
the lumbar spine by 3.0%. HRT increased femoral neck 
and lumbar spine BMD by 2.4 and 3.8%. The researchers 
speculated that the genistein “reduces bone resorption 
markers” and “enhances new bone formation parame-
ters.” As a result, there is a bone mass net gain (Morabito 
et al., 2002). According to the circulating sex hormone 
levels that were assessed after examining the changes in 
the participants after a year, the soy did not produce any 
estrogenic effects. However, the soy did decrease SHBG 
concentrations, which increases the availability of circu-
lating estrogens. Therefore, the soy did affect estrogen 
levels, even though it may not have directly exhibited es-
trogenic qualities. However, to confirm this, it would be 
necessary to measure the endogenous estradiol that is 
circulating. While there are certainly a number of studies 
that show correlation between bone protection and soy, 
there are still too many factors that require closer exam-
ination (Arjmandi et al., 2005).
Conclusion
Many soy- related articles are published annually; howev-
er, there are still numerous questions that require further 
exploration. Questions include whether SBIF is indeed 
harmful or not, how effective of an HRT is soy when it 
comes to menopausal symptoms, whether the effect of 
isoflavones on bone is transitory, and whether soy iso-
flavones and lower doses of antiresorptive agents can 
prevent postmenopausal bone mineral loss. In the United 
States, advisory groups gave their recommendation 
regarding the safety of soy infant formula. “The North 
America Committee on American Academy of Pediatrics 
recommends soy formula only for infants with galacto-
semia or hereditary lactase deficiency and mentions that 
soy formula might be useful for families wishing to avoid 
formula containing animal products.” (Adgent et al., 2018) 
While high consumption may not be advisable for infants, 
Asian postmenopausal women with soy rich diets benefit 
from the isoflavones as shown by the studies mentioned 
above. The efficacy of soy and its isoflavones as an al-
ternative to HRT and as a natural estrogenic source for 
treatment has yet to be determined. 
Although the biological effects of soy hold potential, 
there are limitations, such as low bioavailability and low 
biological estrogenic activity. This has limited the clinical 
applications of genistein to some extent. However, the 
components of soy are promising in terms of being a nat-
ural source of preventative care.
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